HYDROCHLOROTHIAZIDE ADVERSE EVENTS A Descriptive Analysis of Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS)
Fuente:
Zenodo
Guardado en:
| Autor principal: | Nehad Jaser Ahmed |
|---|---|
| Formato: | Recurso digital |
| Publicado: |
Zenodo
2026
|
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
Descriptive Analysis of Ranolazine Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS)
por: Nehad Jaser Ahmed
Publicado: (2026)
por: Nehad Jaser Ahmed
Publicado: (2026)
Descriptive Analysis of DALTEPARIN Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS)
por: Nehad Jaser Ahmed
Publicado: (2026)
por: Nehad Jaser Ahmed
Publicado: (2026)
DOFETILIDE Descriptive Analysis of Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS)
por: Nehad Jaser Ahmed
Publicado: (2026)
por: Nehad Jaser Ahmed
Publicado: (2026)
Labetalol: A Descriptive Analysis of Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS)
por: Nehad Jaser Ahmed
Publicado: (2026)
por: Nehad Jaser Ahmed
Publicado: (2026)
Prazosin Adverse Events: A Descriptive Analysis of the FDA Adverse Event Reporting System (FAERS)
por: Nehad Jaser Ahmed
Publicado: (2026)
por: Nehad Jaser Ahmed
Publicado: (2026)
Descriptive Analysis of Amiloride Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS): A Retrospective Pharmacovigilance Study
por: Nehad Jaser Ahmed
Publicado: (2026)
por: Nehad Jaser Ahmed
Publicado: (2026)
Descriptive Analysis of Alteplase Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS): A Retrospective Pharmacovigilance Study
por: Nehad Jaser Ahmed
Publicado: (2026)
por: Nehad Jaser Ahmed
Publicado: (2026)
Adverse Event Profile of Spiramycin: A Comprehensive Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Nehad Jaser Ahmed
Publicado: (2026)
por: Nehad Jaser Ahmed
Publicado: (2026)
Indications and Adverse Events of Toradol: Based on FDA Adverse Event Reporting System (FAERS)
por: Jiaqi Guo, et al.
Publicado: (2026)
por: Jiaqi Guo, et al.
Publicado: (2026)
Adverse Events Associated With Dabrafenib, Trametinib, and Their Combination Therapy: A Disproportionality Analysis of the FDA Adverse Event Reporting System ( FAERS ) Database
por: Zhenpo Zhang, et al.
Publicado: (2025)
por: Zhenpo Zhang, et al.
Publicado: (2025)
Evaluating the Evolving Real‐World Adverse Events of GLP ‐ 1RAs Using FDA Adverse Event Reporting System ( FAERS )
por: David Stone, et al.
Publicado: (2026)
por: David Stone, et al.
Publicado: (2026)
Pharmacovigilance Analysis of Drug-Induced Rhabdomyolysis Based on the FDA Adverse Event Reporting System (FAERS)
por: Liang, Enpu
Publicado: (2025)
por: Liang, Enpu
Publicado: (2025)
Low‐Dose Oral Minoxidil and Associated Adverse Events: Analyses of the FDA Adverse Event Reporting System ( FAERS ) With a Focus on Pericardial Effusions
por: Aditya K. Gupta, et al.
Publicado: (2024)
por: Aditya K. Gupta, et al.
Publicado: (2024)
A Real‐World Pharmacovigilance Study of Fruquintinib Based on the FDA Adverse Event Reporting System ( FAERS ) Database
por: Yajing Xu, et al.
Publicado: (2025)
por: Yajing Xu, et al.
Publicado: (2025)
ADHD medications and drug withdrawal: A pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database
por: Takumi Ebina, et al.
Publicado: (2026)
por: Takumi Ebina, et al.
Publicado: (2026)
Cardiovascular and Metabolic Adverse Events of Endocrine Therapies in Women with Breast Cancer: A Disproportionality Analysis of Reports in the FDA Adverse Event Reporting System
por: Shaimaa Elshafie, et al.
Publicado: (2024)
por: Shaimaa Elshafie, et al.
Publicado: (2024)
Safety analysis of gepants for migraine treatment: A pharmacovigilance study using the FDA Adverse Event Reporting System ( FAERS ) database
por: Hui Chen, et al.
Publicado: (2026)
por: Hui Chen, et al.
Publicado: (2026)
Comprehensive safety assessment of ribociclib: A real‐world analysis using the FDA Adverse Event Reporting System (FAERS) database
por: Lan Luo, et al.
Publicado: (2025)
por: Lan Luo, et al.
Publicado: (2025)
Aioli: Standardising Drugs in the FDA Adverse Event Reporting System ( FAERS ) to RxNorm and Anatomical Therapeutic Chemical ( ATC ) Codes
por: Rowan E. Parry, et al.
Publicado: (2025)
por: Rowan E. Parry, et al.
Publicado: (2025)
Vismodegib and Sonidegib Are Associated With an Elevated Reporting Odds of Squamous Cell Carcinoma; a Comparative Pharmacovigilance Study of the FDA Adverse Events Reporting System ( FAERS )
por: Patrick Jedlowski, et al.
Publicado: (2025)
por: Patrick Jedlowski, et al.
Publicado: (2025)
FDA Adverse Event Reporting System Essentials: A Reflection on Study Conception
por: Emanuel Raschi, et al.
Publicado: (2025)
por: Emanuel Raschi, et al.
Publicado: (2025)
A Real‐World Study on Adverse Reactions of Belimumab Based on the FDA Adverse Event Reporting System Database
por: Le Hai, et al.
Publicado: (2024)
por: Le Hai, et al.
Publicado: (2024)
Drug‐Related Hypertension: A Disproportionality Analysis Leveraging the FDA Adverse Event Reporting System
por: Hao Zhu, et al.
Publicado: (2025)
por: Hao Zhu, et al.
Publicado: (2025)
A Real‐World Pharmacovigilance Study of FDA Adverse Event Reporting System Events for Obeticholic Acid
por: Le Hai, et al.
Publicado: (2025)
por: Le Hai, et al.
Publicado: (2025)
The Cardiovascular Safety of Antiparkinsonian Drugs—Analysis of Signals in the FDA Adverse Event Report System Database
por: Xin Mu, et al.
Publicado: (2026)
por: Xin Mu, et al.
Publicado: (2026)
Analysis of Predictors of Adverse Events and Mortality Risk Associated With IL‐6 Inhibitors: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database
por: Meilin Fang, et al.
Publicado: (2025)
por: Meilin Fang, et al.
Publicado: (2025)
Bridging FDA Adverse Event Reporting System ( FAERS ) and Clinical Practice: Comprehensive Characterization of Immune Checkpoint Inhibitors Toxicities in Geriatric Lung Cancer Patients
por: Yumeng Tian, et al.
Publicado: (2026)
por: Yumeng Tian, et al.
Publicado: (2026)
Gastrointestinal Perforations Associated With JAK Inhibitors: A Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Adam Goldman, et al.
Publicado: (2024)
por: Adam Goldman, et al.
Publicado: (2024)
A Feasibility Assessment of the FDA Adverse Event Reporting System for the Detection of Cannabis‐Related Safety Signals
por: Priscilla O. M. V. Lopes, et al.
Publicado: (2026)
por: Priscilla O. M. V. Lopes, et al.
Publicado: (2026)
Comparative Post‐Marketing Surveillance of Memantine and Cholinesterase Inhibitors: Cardiovascular Adverse Events With a Focus on Sex Differences Using the FDA Adverse Event Reporting System Database
por: Zinnet Şevval Aksoyalp, et al.
Publicado: (2024)
por: Zinnet Şevval Aksoyalp, et al.
Publicado: (2024)
100 Short Answer Questions about Sexually Transmitted Infections, prepared by Dr. Nehad Jaser Ahmed using Claude
por: Nehad Jaser Ahmed
Publicado: (2026)
por: Nehad Jaser Ahmed
Publicado: (2026)
100 Fill-in-the-Blank Questions about Antimicrobial Prophylaxis in Surgery, prepared by Dr. Nehad Jaser Ahmed using Claude
por: Nehad Jaser Ahmed
Publicado: (2026)
por: Nehad Jaser Ahmed
Publicado: (2026)
100 Short Answer Questions about Infections in Immunocompromised Patients, prepared by Dr. Nehad Jaser Ahmed using Claude
por: Nehad Jaser Ahmed
Publicado: (2026)
por: Nehad Jaser Ahmed
Publicado: (2026)
100 Short Answer Questions about Invasive Fungal Infections, prepared by Dr. Nehad Jaser Ahmed using Claude
por: Nehad Jaser Ahmed
Publicado: (2026)
por: Nehad Jaser Ahmed
Publicado: (2026)
100 Fill-in-the-Blank Questions about Sepsis and Septic Shock, prepared by Dr. Nehad Jaser Ahmed using Claude
por: Nehad Jaser Ahmed
Publicado: (2026)
por: Nehad Jaser Ahmed
Publicado: (2026)
100 Matching Questions about Skin and Soft Tissue Infections prepared by Dr. Nehad Jaser Ahmed using Claude
por: Nehad Jaser Ahmed
Publicado: (2026)
por: Nehad Jaser Ahmed
Publicado: (2026)
100 Fill-in-the-Blank Questions about Tuberculosis, prepared by Dr. Nehad Jaser Ahmed using Claude
por: Nehad Jaser Ahmed
Publicado: (2026)
por: Nehad Jaser Ahmed
Publicado: (2026)
100 Short Answer Questions about INFLUENZA, prepared by Dr. Nehad Jaser Ahmed using Claude
por: Nehad Jaser Ahmed
Publicado: (2026)
por: Nehad Jaser Ahmed
Publicado: (2026)
Adverse Event Assessment of Upadacitinib: A Pharmacovigilance Study Based on the FAERS Database
por: Jiayu Yuan, et al.
Publicado: (2024)
por: Jiayu Yuan, et al.
Publicado: (2024)
Postmarketing Safety Surveillance of Topiramate: A Signal Detection and Analysis Study Based on the FDA Adverse Event Reporting System Database
por: Kai Lin, et al.
Publicado: (2024)
por: Kai Lin, et al.
Publicado: (2024)
Ejemplares similares
-
Descriptive Analysis of Ranolazine Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS)
por: Nehad Jaser Ahmed
Publicado: (2026) -
Descriptive Analysis of DALTEPARIN Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS)
por: Nehad Jaser Ahmed
Publicado: (2026) -
DOFETILIDE Descriptive Analysis of Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS)
por: Nehad Jaser Ahmed
Publicado: (2026) -
Labetalol: A Descriptive Analysis of Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS)
por: Nehad Jaser Ahmed
Publicado: (2026) -
Prazosin Adverse Events: A Descriptive Analysis of the FDA Adverse Event Reporting System (FAERS)
por: Nehad Jaser Ahmed
Publicado: (2026)